MDGL Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.

Investor ContactTina Ventura, IR@madrigalpharma.com

Media ContactChristopher Frates, media@madrigalpharma.com